Insider Selling: Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells $414,801.38 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $12.01, for a total transaction of $414,801.38. Following the completion of the transaction, the chief executive officer directly owned 621,881 shares in the company, valued at $7,468,790.81. The trade was a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jacob Chacko also recently made the following trade(s):

• On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.05, for a total transaction of $638,662.05.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.80, for a total transaction of $1,350,000.00.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC opened at $11.56 on Friday. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.12 and a beta of 1.68. The company has a 50-day simple moving average of $10.39 and a 200-day simple moving average of $8.52.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). As a group, research analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ORIC shares. Zacks Research raised Oric Pharmaceuticals to a “hold” rating in a report on Tuesday, August 12th. LADENBURG THALM/SH SH began coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, July 8th. They issued a “buy” rating and a $15.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Saturday, September 27th. Finally, HC Wainwright dropped their price target on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.29.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its position in shares of Oric Pharmaceuticals by 34.0% during the 4th quarter. Bank of America Corp DE now owns 112,520 shares of the company’s stock worth $908,000 after purchasing an additional 28,570 shares during the last quarter. Two Sigma Advisers LP increased its position in Oric Pharmaceuticals by 14.3% during the fourth quarter. Two Sigma Advisers LP now owns 66,500 shares of the company’s stock worth $537,000 after buying an additional 8,300 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Oric Pharmaceuticals by 54.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,579 shares of the company’s stock worth $287,000 after acquiring an additional 12,545 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Oric Pharmaceuticals by 6.9% in the fourth quarter. Wellington Management Group LLP now owns 186,430 shares of the company’s stock valued at $1,504,000 after acquiring an additional 12,042 shares in the last quarter. Finally, Arizona State Retirement System acquired a new stake in shares of Oric Pharmaceuticals during the first quarter valued at $56,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.